Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer. Issue 2 (February 2019)

• Record Type: Journal Article
• Authors: Moore, Kathleen; Colombo, Nicoletta; Scambia, Giovanni; Kim, Byoung-Gie; Oaknin, Ana; Friedlander, Michael; Lisyanskaya, Alla; Floquet, Anne; Leary, Alexandra; Sonke, Gabe S.; Gourley, Charlie; Banerjee, Susana; Oza, Amit; González-Martín, Antonio; Aghajanian, Carol; Bradley, William; Mathews, Cara; Liu, Joyce; Lowe, Elizabeth S.; Bloomfield, Ralph; DiSilvestro, Paul
• Is Part Of: Obstetrical & gynecological survey. Volume 74:Issue 2(2019)
• Publication Date: 2019-02
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000552695.03241.d6
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from N Engl J Med 2018;379:2495–2505) Standard-of-care therapy for patients newly diagnosed with advanced ovarian cancer consists of frontline cytoreductive surgery and adjuvant platinum chemotherapy. Approximately 70% of these patients have a relapse within 3 years.